CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer
Jin Ho Baek

DOI: https://doi.org/10.12701/yujm.2021.00934

Excel Download

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Cancer Chemotherapy and Pharmacology. 2013;72(2):397-403   Crossref logo
Link1 Link2 Link3

Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer
Cancer Treatment Reviews. 2020;85:101979   Crossref logo
Link1 Link2

Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
Annals of Oncology. 2018;29:viii146   Crossref logo
Link1 Link2 Link3

Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
European Journal of Cancer. 2013;49(14):2968-2971   Crossref logo
Link1 Link2

Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress
Annals of Oncology. 2018;29:v27-v28   Crossref logo
Link1 Link2 Link3

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
Gynecologic Oncology. 2006;101(1):46-54   Crossref logo
Link1 Link2

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
Thoracic Cancer. 2020;11(12):3419-3421   Crossref logo
Link1 Link2 Link3

Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy
European Journal of Cancer. 2017;75:308-309   Crossref logo
Link1 Link2

Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy
Annals of Oncology. 2012;23:ix194-ix195   Crossref logo
Link1 Link2

5051355 Anti-human gastric cancer monoclonal antibody
Biotechnology Advances. 1992;10(1):135   Crossref logo
Link1 Link2